Preventive Activity against Influenza (H1N1) Virus by Intranasally Delivered RNA-Hydrolyzing Antibody in Respiratory Epithelial Cells of Mice

Viruses - Tập 7 Số 9 - Trang 5133-5144
Seungchan Cho1, Ha-Na Youn2, Phuong Mai Hoang1, Sungrae Cho1, Kee-Eun Kim1, Eui‐Joon Kil1, Gunsup Lee1, Mun-Ju Cho1, Juhyun Hong1, Sung-June Byun3, Chang‐Seon Song2, Sukchan Lee1
1Department of Genetic Engineering, Sungkyunkwan University, 2066, Seobu-ro, Jangan-gu, Suwon 16419, Korea
2Avian Disease Laboratory, College of Veterinary Medicine, Konkuk University, 120, Neungdong-ro, Gwangjin-gu, Seoul 05029, Korea
3Animal Biotechnology Division, National Institute of Animal Science (NIAS), Rural Development Administration (RDA), 1500, Kongjwipatjwi-ro, Iseomyeon, Wanju 55365, Korea

Tóm tắt

The antiviral effect of a catalytic RNA-hydrolyzing antibody, 3D8 scFv, for intranasal administration against avian influenza virus (H1N1) was described. The recombinant 3D8 scFv protein prevented BALB/c mice against H1N1 influenza virus infection by degradation of the viral RNA genome through its intrinsic RNA-hydrolyzing activity. Intranasal administration of 3D8 scFv (50 μg/day) for five days prior to infection demonstrated an antiviral activity (70% survival) against H1N1 infection. The antiviral ability of 3D8 scFv to penetrate into epithelial cells from bronchial cavity via the respiratory mucosal layer was confirmed by immunohistochemistry, qRT-PCR, and histopathological examination. The antiviral activity of 3D8 scFv against H1N1 virus infection was not due to host immune cytokines or chemokines, but rather to direct antiviral RNA-hydrolyzing activity of 3D8 scFv against the viral RNA genome. Taken together, our results suggest that the RNase activity of 3D8 scFv, coupled with its ability to penetrate epithelial cells through the respiratory mucosal layer, directly prevents H1N1 virus infection in a mouse model system.

Từ khóa


Tài liệu tham khảo

Tang, 2010, Emerging, novel, and known influenza virus infections in humans, Infect. Dis. Clin. N. Am., 24, 603, 10.1016/j.idc.2010.04.001

Hernandez, 2009, Pneumonia and respiratory failure from swine-origin influenza a (H1N1) in mexico, N. Engl. J. Med., 361, 680, 10.1056/NEJMoa0904252

Huang, S.S., Lin, Z., Banner, D., Leon, A.J., Paquette, S.G., Rubin, B., Rubino, S., Guan, Y., Kelvin, D.J., and Kelvin, A.A. (2013). Immunity toward H1N1 influenza hemagglutinin of historical and contemporary strains suggests protection and vaccine failure. Sci. Rep., 3.

Boltz, 2010, Drugs in development for influenza, Drugs, 70, 1349, 10.2165/11537960-000000000-00000

Sheu, 2011, Dual resistance to adamantanes and oseltamivir among seasonal influenza A(H1N1) viruses: 2008–2010, J. Infect. Dis., 203, 13, 10.1093/infdis/jiq005

Webster, 2011, Oseltamivir-resistant pandemic H1N1 influenza, Can. Med. Assoc. J., 183, E420, 10.1503/cmaj.100313

Flannery, 2014, Interim estimates of 2013–14 seasonal influenza vaccine effectiveness—United States, February 2014, Morb. Mortal. Wkly. Rep., 63, 137

Barr, 2014, Who recommendations for the viruses used in the 2013–2014 northern hemisphere influenza vaccine: Epidemiology, antigenic and genetic characteristics of influenza A(H1N1)pdm09, A(H3N2) and B influenza viruses collected from October 2012 to January 2013, Vaccine, 32, 4713, 10.1016/j.vaccine.2014.02.014

Kim, 2006, Heavy and light chain variable single domains of an anti-DNA binding antibody hydrolyze both double- and single-stranded dnas without sequence specificity, J. Biol. Chem., 281, 15287, 10.1074/jbc.M600937200

Kwon, 2002, Production and characterization of an anti-idiotypic single chain fv that recognizes an anti-DNA antibody, Immunol. Investig., 31, 205, 10.1081/IMM-120016241

Jang, 2009, A nucleic acid-hydrolyzing antibody penetrates into cells via caveolae-mediated endocytosis, localizes in the cytosol and exhibits cytotoxicity, Cell. Mol. Life Sci., 66, 1985, 10.1007/s00018-009-9179-2

Lee, 2014, A nucleic-acid hydrolyzing single chain antibody confers resistance to DNA virus infection in hela cells and c57bl/6 mice, PLoS Pathog., 10, e1004208, 10.1371/journal.ppat.1004208

Jun, 2010, An rna-hydrolyzing recombinant antibody exhibits an antiviral activity against classical swine fever virus, Biochem. Biophys. Res. Commun., 395, 484, 10.1016/j.bbrc.2010.04.032

Hoang, 2015, Development of lactobacillus paracasei harboring nucleic acid-hydrolyzing 3d8 scfv as a preventive probiotic against murine norovirus infection, Appl. Microbiol. Biotechnol., 99, 2793, 10.1007/s00253-014-6257-7

Neutra, 2006, Mucosal vaccines: The promise and the challenge, Nat. Rev. Immunol., 6, 148, 10.1038/nri1777

Illum, 2003, Nasal drug delivery—Possibilities, problems and solutions, J. Control. Release, 87, 187, 10.1016/S0168-3659(02)00363-2

Romeo, 1998, Effects of physicochemical properties and other factors on systemic nasal drug delivery, Adv. Drug Deliv. Rev., 29, 89, 10.1016/S0169-409X(97)00063-X

Patton, 1992, (D) routes of delivery: Case studies: (2) pulmonary delivery of peptides and proteins for systemic action, Adv. Drug Deliv. Rev., 8, 179, 10.1016/0169-409X(92)90002-8

Klingenberg, 2010, Intranasal immunization with an apolipoprotein b-100 fusion protein induces antigen-specific regulatory t cells and reduces atherosclerosis, Arterioscler. Thromb. Vasc. Biol., 30, 946, 10.1161/ATVBAHA.109.202671

Sloat, 2006, Evaluation of the immune response induced by a nasal anthrax vaccine based on the protective antigen protein in anaesthetized and non-anaesthetized mice, J. Pharm. Pharmacol., 58, 439, 10.1211/jpp.58.4.0003

Youn, 2012, Intranasal administration of live lactobacillus species facilitates protection against influenza virus infection in mice, Antivir. Res., 93, 138, 10.1016/j.antiviral.2011.11.004

2005, Technical aspects of immunohistochemistry, Vet. Pathol., 42, 405, 10.1354/vp.42-4-405

Rozen, 2000, Primer3 on the www for general users and for biologist programmers, Methods Mol. Biol., 132, 365

Venables, W.N., and Ripley, B.D. (2002). Modern Applied Statistics with S, Springer.

Catania, 2014, High intensive care unit admission rate for 2013–2014 influenza is associated with a low rate of vaccination, Am. J. Respir. Crit. Care Med., 189, 485, 10.1164/rccm.201401-0066LE

Davis, 2001, Nasal vaccines, Adv. Drug Deliv. Rev., 51, 21, 10.1016/S0169-409X(01)00162-4

Illum, 2002, Nasal drug delivery: New developments and strategies, Drug Discov. Today, 7, 1184, 10.1016/S1359-6446(02)02529-1

Abraham, 1994, Alpha 4-integrins mediate antigen-induced late bronchial responses and prolonged airway hyperresponsiveness in sheep, J. Clin. Investig., 93, 776, 10.1172/JCI117032

Shardonofsky, 1999, Therapeutic efficacy of an anti-il-5 monoclonal antibody delivered into the respiratory tract in a murine model of asthma, J. Allergy Clin. Immunol., 104, 215, 10.1016/S0091-6749(99)70138-7

Anik, 1984, Nasal absorption of nafarelin acetate, the decapeptide [d-nal(2)6)]lhrh, in rhesus monkeys. I, J. Pharm. Sci., 73, 684, 10.1002/jps.2600730523

Simmons, 2006, Fatal outcome of human influenza a (h5n1) is associated with high viral load and hypercytokinemia, Nat. Med., 12, 1203, 10.1038/nm1477

Wang, 2010, Influenza virus-cytokine-protease cycle in the pathogenesis of vascular hyperpermeability in severe influenza, J. Infect. Dis., 202, 991, 10.1086/656044

Suliman, 2001, Prevention of influenza-induced lung injury in mice overexpressing extracellular superoxide dismutase, Am. J. Physiol. Lung Cell. Mol. Physiol., 280, L69, 10.1152/ajplung.2001.280.1.L69

Thông tin
Thông tin xuất bản

Viruses

Tập 7 Số 9

5133-5144

Thông tin tác giả